Winning Stock Forecast: OPKO Health, Inc. (NASDAQ: OPKO) Is Stronger Than Ever With 47.71% In 7 Days

Winning Stock Forecast

 “The improved first quarter results were in line with our expectations, starting 2018 positively coming off challenging fourth quarter 2017 results.  These factors, taken together, reflect progress across the breadth of our commercial and laboratory services.” – Phillip Frost, Chairman and Chief Executive Officer of OPKO Health

[Image Source: www.Annualreports.com]

Over the 7 days period from May 4th to May 11th, 2018 OPKO stock price experienced steep price surge of more than 47%. Taking into account the overall OPKO stock performance indicators for the last quarter, it is reasonable to suggest that this is the consequence of the company’s results achieved in 1Q 2018. Based on the press release on May 8, 2018 the following highlights are important to analyze:

  • Consolidated revenues for the three months ended March 31, 2018 were $254.9 million compared with $266.4 million for the comparable period of 2017
  • Revenue from services were $211.3 million for the three months ended March 31, 2018 compared with $228.6 million for the comparable 2017 period
  • Revenue from products included $3.7 million of revenue from RAYALDEE during the first quarter of 2018
  • Net loss of $43.1 million or $0.08 per share during the three months ended March 31, 2018 compares with a net loss of $34.5 million or $0.06 per share for the comparable period of 2017

The above highlights could not pass unseen by the market and investors observed OPKO stock growth of 47.71% during the above-mentioned period. The below chart illustrates this:

[Source: Google Finance]

At the same time the analyst community mostly took either buy or strong buy position on OPKO stock over the last 4 months, with slightly decreasing number of analysts who took hold positions:

[Source: Yahoo Finance]

On May 4, 2018, I Know First issued a bullish 7 days forecast for OPKO Health (NASDAQ: OPKO). The forecast illustrated a signal of 7.58 and a predictability of 0.2. In accordance with the forecast, OPKO stock returned 47.71% over this period, highlighting the accuracy of the prediction produced by the I Know First algorithm.

Current I Know First subscribers received this bullish OPKO forecast on May 4, 2018.

To subscribe today click here.

Biotech Stocks To Watch

OPKO Health, Inc. (NASDAQ: OPKO), a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing OPK88004, an androgen receptor modulator for benign prostate hypertrophy and other urologic and metabolic conditions; OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity; hGH-CTP, a growth hormone injection that is in Phase III clinical trials; and Factor VIIa drug for hemophilia. In addition, it develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, marketing, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.